The clinical trial, slated to start Tuesday, will test transfusions of blood plasma with antibodies against the novel coronavirus taken from patients who have survived COVID-19 infection.
It is one of two medical interventions announced by New York Gov. Andrew Cuomo Monday. The other involves testing the blood of recovered patients for coronavirus antibodies in an effort to clear them to go back to work.
New York has not disclosed its pharma partner yet, Forbes reported.
Takeda is working on a plasma-based treatment that has been shown to help those with severe acute viral respiratory infections and could be used as a COVID-19 treatment. And Regeneron has isolated hundreds of neutralizing antibodies against the SARS-CoV-2 virus from a humanized mouse model as well as from humans who have recovered from COVID-19.
The New York-based company plans to pick the two best-performing antibodies for a cocktail therapy that can be given to patients fighting infection or to at-risk people before exposure.
Source: Fierce Biotech